Will the attributes of multiparametric MRI permit the creation of a new approach to therapy?

Current Opinion in Urology

Volumn 25, Issue 6, 2015, Pages 518-521

  Moore, Caroline M ^a   Emberton, Mark ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Dietary interventions; MRI; Prostate cancer

Indexed keywords

DUTASTERIDE; ELLAGIC ACID; METFORMIN; SULFORAPHANE;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER SIZE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; EARLY CANCER; HUMAN; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEAT PROCEDURE; REVIEW; TUMOR ABLATION; VASCULARIZATION; BIOPSY; DIET THERAPY; EARLY CANCER DIAGNOSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PROCEDURES; PROSTATIC NEOPLASMS; RISK FACTOR; TIME FACTOR; TUMOR VOLUME; WATCHFUL WAITING;

BIOPSY; EARLY DETECTION OF CANCER; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; RISK FACTORS; TIME FACTORS; TUMOR BURDEN; WATCHFUL WAITING;

EID: 84943183897     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0000000000000214     Document Type: Review

References (21)

1. Kirkham AP, Emberton M, Allen C. How good is MRI at detecting and characterising cancer within the prostate? Eur Urol 2006; 50:1163-1174.
2. Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 2015; 313:390-397.
3. Panebianco V, Barchetti F, Sciarra A, et al. Multiparametric magnetic reso-nance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. Urol Oncol 2015; 33:; 17.e1-7.
4. Prostate Cancer Diagnosis and Treatment. National Institute for Health and Care Excellence 2014. https://www.nice.org.uk/guidance/cg175. [Accessed 25 August 2015].
5. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012; 22:746-757.
6. Kirkham AP, Haslam P, Keanie JY, et al. Prostate MRI: who, when, and how? Report from a UK consensus meeting. Clin Radiol 2013; doi 10.1016/ j.crad.2013.03.030. [Epub ahead of print]
7. Panagiotaki E, Chan RW, Dikaios N, et al. Microstructural characterization of normal and malignant human prostate tissue with vascular, extracellular, and restricted diffusion for cytometry in tumours magnetic resonance imaging. Invest Radiol 2015; 50:218-227.
8. Wilson DM, Kurhanewicz J. Hyperpolarized 13C MR for molecular imaging of prostate cancer. J Nucl Med 2014; 55:1567-1572.
9. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
10. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
11. Desar IM, van Herpen CM, van Laarhoven HW, et al. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev 2009; 35:309-321.
12. Giovannucci E, Rimm EB, Liu Y, et al. A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst 2002; 94:391-398.
13. Gontero P, Marra G, Soria F, et al. A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or ''chemopromotion''? Prostate 2015; 75:1177-1186.
14. Naiki-Ito A, Chewonarin T, Tang M, et al. Ellagic acid, a component of pomegranate fruit juice, suppresses androgen-dependent prostate carcino-genesis via induction of apoptosis. Prostate 2015; 75:151-160.
15. Thomas R, Williams M, Sharma H, et al. A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer - the U.K. NCRN pomi-t study. Prostate Cancer Prostatic Dis 2014; 17:180-186.
16. Nordström T, Clements M, Karlsson R, et al. The risk of prostate cancer for men on aspirin, statin or antidiabetic medications. Eur J Cancer 2015; 51:725-733.
17. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The selenium and vitamin E cancer prevention trial (SELECT). JAMA 2009; 301:39-51.
18. Klein EA, Thompson IM, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT). JAMA 2011; 306:1549-1556.
19. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349:215-224.
20. Fleshner NE, Lucia MS, Egerdie B, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet 2012; 379:1103-1111.
21. Robertson NL, Moore CM, Ambler G, et al. MAPPED study design: a 6 month randomised controlled study to evaluate the effect of dutasteride on prostate cancer volume using magnetic resonance imaging. Contemp Clin Trials 2012; 34:80-89.